{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-098289","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2024-08-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.258907+00:00","generated_at":"2026-05-31T08:39:50.813414+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kineta reopens VISTA-101 trial; 30 of 39 patients enrolled; KVA12123 safe","bullets":["Kineta reopened enrollment in VISTA-101 Phase 1/2 trial for KVA12123; expects full enrollment by end of 2024.","30 of projected 39 patients enrolled; cleared 5th of 6 monotherapy dose levels and 2 of 4 combination cohorts.","Initial results showed partial response and stable disease in combo cohorts; durable stable disease in monotherapy.","KVA12123 demonstrated no dose-limiting toxicities and no CRS-associated cytokines at any dose level.","TuHURA has exclusive right to negotiate acquisition until Oct 1, 2024 (extendable) after $5M nonrefundable payment."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-098289","json":"https://secwatch.observer/filing/0000950170-24-098289.json","markdown":"https://secwatch.observer/filing/0000950170-24-098289.md","text":"https://secwatch.observer/filing/0000950170-24-098289.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000095017024098289/0000950170-24-098289-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000095017024098289/ktra-20240819.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:39:50.813414+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}